Yes, Medicare drug coverage can include step therapy, and it can affect both Medicare Advantage and Part D prescriptions. Medicare Advantage plans may apply step therapy to certain Part B drugs, while Part D plans have long used it for pharmacy medications. It generally applies only to new prescriptions, not ones you are already taking. If a non-preferred drug is what you need, ask your prescriber right away to document medical necessity or file an exception.
TL;DR:
- Step therapy generally applies only to new prescriptions, requiring trials of preferred drugs before expensive alternatives are covered.
- Medicare Advantage plans began applying step therapy to Part B drugs in 2019, creating overlap with Part D rules for injected or infused medications.
- Prescribers can request exceptions with clinical justification, often expedited if delaying treatment risks health complications, with structured appeal options.
- Plan disclosures about step therapy must be clear in notices and coverage documents, and support programs are mandated when applying to Part B drugs.
- Acting early by involving prescribers in exception requests before delays happen significantly improves access to necessary medications.
Table of Contents
- What Step Therapy Means Under Medicare Rules
- How Step Therapy Works Across Part B, Part D, and Medicare Advantage
- Requesting an Exception: Timelines and the Appeals Ladder
- Your Protections: What Plans Must Disclose
- Your Action Checklist When a Prescription Hits a Step Therapy Wall
- How Step Therapy Can Affect Access and Outcomes
- Drug Classes Commonly Subject to Step Therapy
- Recent Regulatory Changes Shaping Step Therapy Rules
- Step Therapy Alongside the Coverage Gap and Extra Help
- Why Acting Early Beats Waiting for a Denial
- Getting Help With Step Therapy and Medicare Plan Choices
- FAQ
- Sources
What Step Therapy Means Under Medicare Rules
Step therapy requires you to try a preferred, usually less expensive medication before your plan will cover a pricier, non-preferred alternative for the same condition. It is one of several plan rules insurers use to manage spending while still steering patients toward treatments with solid clinical evidence behind them.
Step therapy is often confused with prior authorization, but they work differently. Prior authorization asks your plan to approve a drug before it covers it, based on medical need. Step therapy adds a sequence: try to drug A first, and only move to drug B if A fails or cannot be used.
A few things worth knowing before a prescription gets denied at the pharmacy:
- Step therapy typically applies to new prescriptions or new drug administrations, not treatments you already started.
- Many plans grandfather existing therapies, meaning a switch mid-treatment is less common than beneficiaries fear.
- Part D plans have used step therapy for pharmacy-dispensed drugs for years, so this is not a new concept for prescription coverage.
- Medicare Advantage plans may now apply similar rules to certain drugs administered in a doctor’s office.
How Step Therapy Works Across Part B, Part D, and Medicare Advantage
The distinction between Part B and Part D drugs matters because it determines which rules apply. Part B generally covers drugs administered by a physician, such as infusions or injections given in a clinical setting. Part D covers medications you pick up at a pharmacy and typically self-administer.
Until a few years ago, step therapy was mostly a Part D tool. That changed with a CMS fact sheet permitting Medicare Advantage plans to apply step therapy to Part B drugs starting in 2019. The practical effect: if you take a physician-administered medication through an MA plan, you may need to try a preferred option first, just as Part D enrollees have for pharmacy drugs.
For MAPD plans, which combine Advantage and drug coverage, this creates overlapping sequences to track:
- A Part D step may apply before a pharmacy drug is approved.
- A separate Part B step may apply before an infused or injected drug is approved.
- Both steps can require prior authorization in addition to the sequencing rule.
- Your current, ongoing Part B therapy is generally protected and shouldn’t be disrupted by a new step rule.
Checking your formulary and your plan’s drug management program before a renewal or a new diagnosis saves a lot of back-and-forth later. Our Medicare Advantage overview breaks down how these plans structure drug benefits.
Requesting an Exception: Timelines and the Appeals Ladder
When step therapy stands between you and a drug your prescriber believes you need, you have a formal path to request an exception. Your prescriber submits a supporting statement explaining why the preferred drug is medically inappropriate, unsafe, or has already failed for you. Medicare’s appeals guidance outlines what that statement and request should include.
- Ask your prescriber to submit a coverage determination or exception request with clinical justification.
- Mark the request “expedited” if waiting for a standard decision could jeopardize your health.
- Expect a standard decision within the plan’s stated timeframe, and an expedited one often resolved within 72 hours.
- If denied, file a redetermination, the first of five possible appeal levels, within the deadline on your denial notice.
- Escalate to higher appeal levels, including an independent review entity, if the redetermination is also denied.
Pro Tip: Ask your prescriber’s office for copies of prior lab results, failed-treatment notes, or allergy records before submitting the request. A thin file is the most common reason exceptions get delayed.
The appeals process for Medicare drug plans exists specifically for situations like this, and expedited review is available whenever a delay could worsen your condition.


Your Protections: What Plans Must Disclose
Medicare Advantage plans applying step therapy to Part B drugs are not left to do so quietly. CMS guidance requires that plans disclose these rules clearly, and that they pair any Part B step therapy with real support for the patient.
- Plans must disclose Part B step therapy requirements in the Annual Notice of Change, due by September 30, and the Evidence of Coverage, due by October 15.
- MA plans applying Part B step therapy must offer a drug management care coordination program, though your participation in it is voluntary.
- Step therapy cannot be used to disrupt medications you are already stable on, and it must respect national and local coverage determinations.
- Your EOC and plan website are the most reliable places to check which drugs carry a step therapy requirement this year.
If you cannot find the language in your plan documents, call your plan’s member services line and ask directly whether a specific drug carries a step therapy requirement. Our breakdown of Part D plan mechanics explains where formulary and utilization rules typically show up in those documents.
Your Action Checklist When a Prescription Hits a Step Therapy Wall
A denial at the pharmacy counter or a letter from your plan does not mean the conversation is over. Work through these steps in order.
- Call your prescriber’s office and explain exactly what the plan denied and why.
- Pull up your plan’s Evidence of Coverage or formulary to confirm the step therapy requirement and the preferred alternative.
- Have your prescriber file a coverage determination or exception request with a written statement of medical necessity.
- Ask for expedited handling if a delay would put your health at risk.
- If denied, file a redetermination immediately and track every deadline on the notice.
Gather your medical records, any prior paid claims showing you already tried the preferred drug, your prescriber’s statement, and copies of every denial letter before you start. Keep a simple log of dates and names for every call.
Pro Tip: If a request stalls past its stated timeframe with no response, contact your State Health Insurance Assistance Program or call 1-800-MEDICARE. Open Enrollment is also a chance to compare plans if one consistently gives you trouble.
How Step Therapy Can Affect Access and Outcomes
Step therapy is built around a tradeoff: it steers spending toward cheaper, well-studied drugs first, but it can slow access to the medication a prescriber originally wanted to use. For many conditions, the preferred drug works just as well and the sequencing causes little more than a short delay.
The risk shows up when a condition is progressing quickly or when a patient has already failed the preferred option in the past without that history being on file with the new plan. A gap in paperwork can turn what should be a quick exception into weeks of waiting. That is part of why CMS requires care coordination support when MA plans apply step therapy to Part B drugs: the goal is to catch these situations early rather than let a patient go without treatment while an appeal works through the system.
The practical takeaway for beneficiaries and caregivers is to treat step therapy as a timing issue to manage proactively, not a wall that cannot be addressed. Keeping prescribers informed about prior treatment history, and requesting exceptions as soon as a new prescription is written rather than after a denial arrives, keeps most delays short.
Drug Classes Commonly Subject to Step Therapy
Step therapy tends to cluster around drug classes where multiple treatment options exist and cost differences between them are significant. Common categories include certain biologics used for autoimmune conditions, some cancer-supportive therapies, select diabetes medications, and specialty drugs administered by infusion or injection under Part B.
Newer, high-cost medications in a therapeutic class are especially likely to carry a step therapy requirement, since plans often want patients to try an established, lower-cost option first. This includes some newer injectable medications for chronic conditions where older, generic alternatives exist. If you are prescribed a newly approved or brand-name drug, it is worth asking upfront whether your plan requires a step before covering it, rather than finding out at the pharmacy.
Because formularies and step therapy lists change from plan to plan and year to year, there is no universal list that applies across all Medicare coverage. Checking your specific plan’s formulary and Evidence of Coverage each year remains the only reliable way to know which drugs in your regimen might require a step.
Recent Regulatory Changes Shaping Step Therapy Rules
The most significant shift in recent years came through CMS guidance allowing Medicare Advantage plans to apply step therapy to Part B drugs starting January 1, 2019, a change detailed in the HPMS memo issued in August 2018. That memo reversed an earlier prohibition and laid out the procedural guardrails plans must follow, including look-back protections for existing therapies and specific placement requirements for disclosures in plan documents.
Since then, oversight has focused less on whether step therapy is allowed and more on how transparently it is applied. Regulators have pushed plans to make step therapy requirements visible in the ANOC and EOC rather than buried in separate policy documents, and to pair any Part B step therapy with the care coordination support described earlier.
Reporting has also flagged a separate concern: some step-therapy-like restrictions get embedded inside broader prior authorization criteria rather than labeled explicitly as step therapy. If a prescriber or pharmacy mentions a prior authorization edit that references trying another drug first, it is functioning the same way, even without the step therapy label attached, and the same exception rights generally apply.
Step Therapy Alongside the Coverage Gap and Extra Help
Step therapy and the other major Part D protections work independently, but they interact in practical ways. If a step therapy requirement delays access to a drug, that delay does not change your underlying Extra Help eligibility or the cost-sharing structure the program provides once a drug is approved. Extra Help still lowers your copays for covered drugs regardless of whether you reached them through the preferred or the exception path.


The Part D coverage gap, often called the donut hole, also runs independently of step therapy. Whether a drug cleared a step therapy requirement or was approved outright, your spending toward the coverage gap threshold is tracked the same way once the plan approves and pays for it. The practical concern is timing: a drawn-out exception process can delay when a costly drug starts counting toward your spending totals for the year, which matters most for beneficiaries watching their out-of-pocket costs closely.
Neither program offers a shortcut around step therapy itself. If a drug requires a step, Extra Help and the coverage gap affect what you pay once it is approved, not whether the step requirement applies in the first place.
Why Acting Early Beats Waiting for a Denial
Most step therapy problems I see could have been resolved faster if the exception request went in in February, when a doctor wrote the prescription, instead of in July after a pharmacy denial. Advisors who read EOCs regularly can spot a step therapy clause before it becomes a crisis, help collect the right documentation, and keep deadlines from slipping. The protections exist. Using them early, with your prescriber involved from the start, is what makes them work.
— Zach
Getting Help With Step Therapy and Medicare Plan Choices
Reading an Evidence of Coverage line by line to find a step therapy clause is tedious, and most people have better things to do with an afternoon. We review plan documents for clients regularly, so we can flag a step therapy requirement, a formulary gap, or a care coordination program before it turns into a denied prescription.


Our agents work with various Medicare Advantage Plans, Medicare Supplements, and Prescription Drug Plans from multiple carriers, which means we can compare how different plans handle step therapy before you commit to one. We offer:
- A plan and formulary review to check for step therapy or prior authorization rules tied to your current medications.
- Guidance on filing an exception or appeal if a plan has already denied a drug.
- Support comparing Medicare Advantage and Part D options during Open Enrollment if your current plan keeps getting in the way.
As a licensed insurance agency, we earn commissions from the carriers we work with, not from you, so there is no added cost for sitting down with us. If a step therapy rule is standing between you and a medication you need, get a free Medicare roadmap and we will walk through your options together.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
What is step therapy in Medicare?
Step therapy is a rule requiring you to try a preferred, typically lower-cost drug before your Medicare drug plan will cover a more expensive, non-preferred alternative for the same condition. It applies to Part D pharmacy drugs and, for some Medicare Advantage plans, to certain Part B drugs administered in a clinical setting.
What are the five treatments that Medicare won’t cover?
Medicare does not maintain a public list of exactly five excluded treatments, and coverage exclusions vary by plan, drug, and medical necessity rules. Generally excluded categories include drugs for cosmetic use, fertility treatments, and some over-the-counter medications, though specifics depend on your plan’s formulary and documentation.
What is considered step therapy for Mounjaro?
Step therapy for a drug like Mounjaro would mean a plan requires you to try a different, usually less expensive diabetes or weight-management medication first before covering it, if your plan places it in a non-preferred tier. Whether this applies depends entirely on your specific Part D or Medicare Advantage plan’s formulary, so check your Evidence of Coverage or call member services to confirm.
How many therapy sessions will Medicare pay for?
Step therapy for drugs is a different Medicare rule from mental health therapy session limits. Medicare Part B covers outpatient mental health services based on medical necessity rather than a fixed session cap, with standard coinsurance applying to each visit.
Sources
- Medicare
- CMS — Medicare Advantage prior authorization and step therapy for Part B drugs (fact sheet)
Recommended
Request a No Obligation Phone Call





Get Connected